n-benzyloxycarbonylprolylprolinal has been researched along with talabostat in 2 studies
| Studies (n-benzyloxycarbonylprolylprolinal) | Trials (n-benzyloxycarbonylprolylprolinal) | Recent Studies (post-2010) (n-benzyloxycarbonylprolylprolinal) | Studies (talabostat) | Trials (talabostat) | Recent Studies (post-2010) (talabostat) |
|---|---|---|---|---|---|
| 39 | 0 | 7 | 33 | 4 | 17 |
| Protein | Taxonomy | n-benzyloxycarbonylprolylprolinal (IC50) | talabostat (IC50) |
|---|---|---|---|
| Kynurenine 3-monooxygenase | Rattus norvegicus (Norway rat) | 0.066 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.98 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.1666 | |
| Prolyl endopeptidase | Homo sapiens (human) | 1.8476 | |
| Prolyl endopeptidase FAP | Mus musculus (house mouse) | 0.0673 | |
| Prolyl endopeptidase FAP | Homo sapiens (human) | 0.0792 | |
| Dipeptidyl peptidase 8 | Homo sapiens (human) | 0.0113 | |
| Dipeptidyl peptidase 9 | Homo sapiens (human) | 2.2681 | |
| Dipeptidyl peptidase 2 | Homo sapiens (human) | 0.0437 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Cesco, S; Di Trani, J; Dufresne, C; Janmamode, N; Kurian, J; Mittermaier, AK; Moitessier, N; Patrascu, MB; Plescia, J; Wahba, AS | 1 |
| Dufresne, C; Hédou, D; Labarre, A; Mittermaier, A; Moitessier, N; Plescia, J; Pousse, ME | 1 |
2 other study(ies) available for n-benzyloxycarbonylprolylprolinal and talabostat
| Article | Year |
|---|---|
Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α.
Topics: Dose-Response Relationship, Drug; Endopeptidases; Enzyme Inhibitors; Gelatinases; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Prolyl Oligopeptidases; Quantum Theory; Serine Endopeptidases; Structure-Activity Relationship | 2019 |
Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.
Topics: Endopeptidases; Enzyme Inhibitors; Humans; Membrane Proteins; Neoplasms; Prolyl Oligopeptidases; Serine Endopeptidases | 2022 |